key: cord-0982923-u77iw45b
authors: Brunner-Ziegler, Sophie; Spath, Tibor; Kornek, Gabriela; König, Franz; Parschalk, Bernhard; Schnetzinger, Maximilian; Straßl, Robert Paul; Savic, Rebeka; Foit, Andrea; Resch, Helene; Thalhammer, Florian
title: SARS-CoV-2 vector and m-RNA based vaccines with respect to postvaccination infections among staff of a tertiary care hospital
date: 2021-12-13
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.11.023
sha: e5def6419b3380aa265a311a2c5a82e85e426be0
doc_id: 982923
cord_uid: u77iw45b

OBJECTIVES: The identification of SARS-CoV-2 antigen or RNA in respiratory specimens ≥14 days after administration of all recommended doses of authorized COVID-19 vaccines is defined as „breakthrough infection“. In the present investigation m-RNA and vector based SARS-CoV-2 vaccines were analysed with respect to postvaccination infections in vaccinated hospital employees. METHODS: 8 553 staff members were vaccinated with BNT162b2 (47%) or ChAdOx1-S (53%) between January and May 2021. In a retrospective observational cohort study, incidence of SARS-CoV-2 postvaccination infections was analysed in relation to demographic data, viral load, virus variants, vaccine brand and vaccination status at time of positive PCR test (“fully vaccinated” (≥14 days since second dose), “partially vaccinated” (>21 days since first, but < 14 days after second dose), “insufficiently vaccinated” (<22 days since first dose)). RESULTS: Within the follow-up period, ending on July 31(st), 2021, person-time at risk adjusted monthly rates for SARS-CoV-2 postvaccination infections were 0·18% (BNT162b2) and 0·57% (ChAdOx1-S) for insufficiently, 0·34% (BNT162b2) and 0·32% (ChAdOx1-S) for partially and 0·06% (BNT162b2) and 0·04% (ChAdOx1-S) for fully vaccinated participants. The two vaccine types did not differ with respect to hazard ratios for none of the respective postvaccination infection types. No cases of COVID-19 related hospitalizations or deaths were reported. Genotyping of positive PCR specimens revealed 42 variant of concerns: B.1.1.7 (Alpha variant; n=34); B.1.351 (Beta variant; n=2), B.1.617.2 (Delta variant; n=6). CONCLUSIONS: BNT162b2 and ChAdOx1-S are both effective in preventing breakthrough infections, however, it seems important, that all recommended vaccine doses are administered.

According to the US CDC definition the identification of SARS-CoV-2 antigen or RNA in a respiratory specimen collected from a person ≥14 days after completing all recommended doses of authorized COVID-19 vaccine series is defined as "breakthrough infection" [1] and described to occur at a prevalence of around 1: 10 000 in fully vaccinated persons [1] [2] [3] [4] .

Data on virological characteristics and potential ongoing transmission risks, especially of mildly symptomatic or asymptomatic SARS-CoV-2 postvaccination infections remains limited, as observational studies predominantly have focused on endpoints such as critical illness, hospitalization requirement and death so far [5] [6] [7] [8] , most of them without addressing variation by specific vaccines.

Most notably, information on respiratory SARS-CoV-2 RNA detection after vaccination in temporal relation to the individual vaccination date is scarce. As a consequence the comparison between the diverging definitions of immunization of "14 days after the second vaccination (CDC)" versus "21 days after the first vaccine dose administration", respectively is missing.

The purpose of the present investigation was to characterise the incidence and distribution of SARS- During the entire period, all hospital employees, independent of their vaccination status, were obligated to continue routine testing for SARS-CoV-2 at least once weekly by nasopharyngeal or nasal COVID-19 Antigen Rapid Test Device (Abbott®), according to the test policy of the hospital. Any postvaccination SARS-CoV-2 antigen detection in a respiratory specimen had to be confirmed by nasopharyngeal polymerase chain reaction (PCR) testing. All postvaccination SARS-CoV-2 infections were reported to the hospital´s "COVID-19-Tracing Team" (CTT), which was responsible for isolation demands and contact tracing. In the present retrospective observational cohort study SARS-CoV-2 infection incidence and distribution in vaccinated staff members were analysed in relation to demographic data, vaccine brands and vaccine administration dates. The final cut off date of follow-up to include newly diagnosed postvaccination infections into the present report was July 31 st , 2021.

Vaccination status at the time of positive PCR test result was categorized into three groups and arbitrarily defined as A) fully vaccinated (≥14 days had elapsed since the second vaccine dose), B) partially vaccinated (>21 days had elapsed since the first vaccine dose, but < than 14 days after the second dose) and C) insufficiently vaccinated (<22 days had elapsed since the first vaccine dose).

According to the CDC definition the term "breakthrough infection" was allocated to group A (confirmed SARS-CoV-2 infection ≥14 days after termination of all recommended vaccine doses). We used descriptive statistics and reported counts and proportions for categorical data and measures of distribution (median (interquartile range, IQR) or mean (± standard deviation, SD)) for continuous data. Chi square test and independent samples T test and analysis of variance were used for group comparison. Postvaccination infection rates were standardised by the number of person-days at risk with regard to the three vaccination groups (insufficiently, partially and fully vaccinated participants), by dividing the number of cases by the sum of days at risk. As numbers are quite low, we report the 30 days (=monthly) infection rates. As we had access to aggregated data for uninfected vaccinees only (see limitation section) we had to make simpliciations with regard to the interval between the first and second vaccine dose administration. Based on the recommendations of the Austrian national vaccination board we assumed 11 weeks for ChAdOx1-S and three weeks for BNT162b2. Simplified cox´regression analysis was performed for comparing ChAdOx1-S against BNT162b2 with respect to hazard ratios for postvaccination infections for the three respective vaccination groups. All statistical analyses were performed using a standard IBM SPSS software package, version 27.

The vaccination program took place in winter/spring 2021, with the earliest vaccination on January 12 th , 2021 and the latest on May 27 th , 2021. Willingness to participate was extremely high (>95%).

Since SARS-CoV-2 vaccination of 8 553 hospital employees had started, a total of 78 postvaccination infection cases (25 vaccinated with BNT162b2 and 53 vaccinated with ChAdOx1-S) after administration of a minimum of one dose of vaccination had been identified by the end of July 2021.

Within the study and follow-up period, ending on July 31 st , 2021, the person-time at risk adjusted monthly rates for postvaccination infections were 0·18% (BNT162b2) and 0·57% (ChAdOx1-S) for insufficiently vaccinated participants, 0·34% (BNT162b2) and 0·32% (ChAdOx1-S) for partially vaccinated participants and 0·06% (BNT162b2) and 0·04% (ChAdOx1-S) for fully vaccinated participants. There was no difference between the two vaccine brands with respect to hazard ratios for none of the respective postvaccination infection types. No COVID-19 related need for hospitalization or death was reported. Table 1 and Figure 1 (postvaccination infection cases did not differ compared to the overall cohort of participants of the vaccination program with regard to age and gender; data not shown). The chronological distribution of these 78 postvaccination infection cases in relation to first and second vaccination dates and date of positive PCR test result is displayed in Figure 2 . Allocation of breakthrough infections to professional groups showed highest counts in the nursing personnel (n=13), followed by the medical and diagnostic service personnel (n=11) and the medical personnel (n=8) with a more or less balanced distribution across the remaining groups. Prevalence of detailed SARS-CoV-2 induced symptoms at time of positive testing, which were recorded by telephone interview through a team of four physicians is presented in Table 2 , Part A.

Genotyping of positive PCR specimens revealed variants of concern (VOC) in 42 cases, including B. Table 2 , Part B.

J o u r n a l P r e -p r o o f Seite 7 In the cohort of 8 553 employees, in whom at least one vaccine dose of BNT162b2 or ChAdOx1-S vaccine had been administrated, occurrence of postvaccination infection was substantially higher than previously reported [1] [2] [3] [4] 9] . This discrepancy suggests that earlier numbers of reported breakthrough cases are likely a substantial undercount of infections among vaccinated people, as vaccinees with infections, who are asymptomatic or experience mild illness might not seek testing proactively.

Even if all infected employees of the present investigation were either asymptomatic or at least suffering from mild to moderate COVID-19 -like symptoms and none required hospitalization, available Published data on sex distribution of postvaccination infections vary from favouring either women [12] or men [8] to reflecting the entire population [1] . With respect to the present investigation, we interpret the higher percentage of postvaccination infections in women as a consequence of the higher proportion of females within the hospital staff. In the same way, highest absolute counts of postvaccination infections in health care staff member groups with direct patient contact rather reflect the higher proportion of those groups within tertiary health care institutions than an effective higher risk for a postvaccination infection. protection against SARS-CoV-2 infections it seems essentially important, however, that all recommended vaccine doses are administered.

We declare no conflicting interests.

This study received no funding. J o u r n a l P r e -p r o o f 

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening

Deaths involving COVID-19 by vaccination status, England: daths occurring between 2

C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity

IVY Network; HAIVEN Investigators. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years -United States

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization